Intratracheal Bleomycin Aerosolization: The Best Route of Administration for a Scalable and Homogeneous Pulmonary Fibrosis Rat Model?

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Robbe, Alexandre ^a   Tassin, Alexandra ^a   Carpentier, Justine ^a   Declèves, Anne Emilie ^a   Mekinda Ngono, Zita Léa ^b   Nonclercq, Denis ^a   Legrand, Alexandre ^a  

^a UNIVERSITY OF MONS   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CEFUROXIME; COLLAGEN;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; ASSESSMENT OF HUMANS; BLEOMYCIN-INDUCED PULMONARY FIBROSIS; CONTROLLED STUDY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIMIT OF QUANTITATION; LUNG LAVAGE; LUNG LOBE; MALE; MODIFIED ASHCROFT SCALE; MYOFIBROBLAST; NONHUMAN; POSTOPERATIVE INFECTION; RAT; RAT MODEL; WISTAR RAT; ANIMAL; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODEL; DRUG EFFECTS; HUMAN; INTRATYMPANIC DRUG ADMINISTRATION; LUNG; PATHOLOGY; PULMONARY FIBROSIS;

ANIMALIA; RATTUS; RODENTIA;

ANIMALS; BLEOMYCIN; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; HUMANS; INJECTION, INTRATYMPANIC; LUNG; MALE; PULMONARY FIBROSIS; RATS;

EID: 84929629792     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/198418     Document Type: Article

References (39)

1. H. V. Woodcock and T. M. Maher, "The treatment of idiopathic pulmonary fibrosis," F1000Prime Reports, vol. 6, article 16, 2014.
2. J. R. Covvey and E. E. Mancl, "Recent evidence for pharmacological treatment of idiopathic pulmonary fibrosis," Annals of Pharmacotherapy, vol. 48, no. 12, pp. 1611-1619, 2014.
3. S. D. Nathan, O. A. Shlobin, N. Weir et al., "Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium," Chest, vol. 140, no. 1, pp. 221-229, 2011.
4. I. V. Yang, "Epigenomics of idiopathic pulmonary fibrosis," Epigenomics, vol. 4, no. 2, pp. 195-203, 2012.
5. C. Kuhn III, J. Boldt, T. E. King Jr., E. Crouch, T. Vartio, and J. A. McDonald, "An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis," American Review of Respiratory Disease, vol. 140, no. 6, pp. 1693-1703, 1989.
6. B. B. Moore and C. M. Hogaboam, "Murine models of pulmonary fibrosis," American Journal of Physiology - Lung Cellular and Molecular Physiology, vol. 294, no. 2, pp. L152-L160, 2008.
7. B. C. Willis, R. M. DuBois, and Z. Borok, "Epithelial origin of myofibroblasts during fibrosis in the lung," Proceedings of the American Thoracic Society, vol. 3, no. 4, pp. 377-382, 2006.
8. B. C. Willis, J. M. Liebler, K. Luby-Phelps et al., "Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-β1: potential role in idiopathic pulmonary fibrosis," The American Journal of Pathology, vol. 166, no. 5, pp. 1321-1332, 2005.
9. K. K. Kim, M. C. Kugler, P. J. Wolters et al., "Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 35, pp. 13180-13185, 2006.
10. J. W. Lown and S. K. Sim, "The mechanism of the bleomycin-induced cleavage of DNA," Biochemical and Biophysical Research Communications, vol. 77, no. 4, pp. 1150-1157, 1977.
11. E. A. Sausville, J. Peisach, and S. B. Horwitz, "A role for ferrous ion and oxygen in the degradation of DNA by bleomycin," Biochemical and Biophysical Research Communications, vol. 73, no. 3, pp. 814-822, 1976.
12. F. Chua, J. Gauldie, and G. J. Laurent, "Pulmonary fibrosis: searching for model answers," The American Journal of Respiratory Cell and Molecular Biology, vol. 33, no. 1, pp. 9-13, 2005.
13. M. Kolb, P. J. Margetts, T. Galt et al., "Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin," American Journal of Respiratory and Critical Care Medicine, vol. 163, no. 3, pp. 770-777, 2001.
14. S. N. Giri, D. M. Hyde, and M. A. Hollinger, "Effect of antibody to transforming growth factor β on bleomycin induced accumulation of lung collagen in mice," Thorax, vol. 48, no. 10, pp. 959-966, 1993.
15. Q. Wang, Y. Wang, D. M. Hyde et al., "Reduction of bleomycin induced lung fibrosis by transforming growth factor β soluble receptor in hamsters," Thorax, vol. 54, no. 9, pp. 805-812, 1999.
16. R. S. Thrall, J. R. McCormick, R. M. Jack, R. A. McReynolds, and P. A. Ward, "Bleomycin-induced pulmonary fibrosis in the rat. Inhibition by indomethacin," The American Journal of Pathology, vol. 95, no. 1, pp. 117-130, 1979.
17. M. A. Mouratis and V. Aidinis, "Modeling pulmonary fibrosis with bleomycin," Current Opinion in Pulmonary Medicine, vol. 17, no. 5, pp. 355-361, 2011.
18. N. Limjunyawong, W. Mitzner, and M. R. Horton, "A mouse model of chronic idiopathic pulmonary fibrosis," Physiological Reports, vol. 2, no. 2, Article ID e00249, 2014.
19. R. Peng, S. Sridhar, G. Tyagi et al., "Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for 'active' disease," PLoS ONE, vol. 8, no. 4, Article ID e59348, 2013.
20. K. E. Driscoll, D. L. Costa, G. Hatch et al., "Intratracheal instillation as an exposure technique for the evaluation of respiratory tract toxicity: uses and limitations," Toxicological Sciences, vol. 55, no. 1, pp. 24-35, 2000.
21. P. Vogel, V. R. Rivera, M. L. M. Pitt, and M. A. Poli, "Comparison of the pulmonary distribution and efficacy of antibodies given to mice by intratracheal instillation or aerosol inhalation," Laboratory Animal Science, vol. 46, no. 5, pp. 516-523, 1996.
22. D. Vansthertem, A. Gossiaux, A.-E. Declèves et al., "Expression of nestin, vimentin, and NCAM by renal interstitial cells after ischemic tubular injury," Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 193259, 10 pages, 2010.
23. R.-H. Hübner, W. Gitter, N. E. El Mokhtari et al., "Standardized quantification of pulmonary fibrosis in histological samples," BioTechniques, vol. 44, no. 4, pp. 507-517, 2008.
24. J. D. Williamson, L. R. Sadofsky, and S. P. Hart, "The pathogenesis of bleomycin-induced lung injury in animals and its applicability to human idiopathic pulmonary fibrosis," Experimental Lung Research, 2014.
25. S. H. Phan, "The myofibroblast in pulmonary fibrosis," Chest, vol. 122, pp. 286S-289S, 2002.
26. A. Günther, N. Lübke, M. Ermert et al., "Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits," The American Journal of Respiratory and Critical Care Medicine, vol. 168, no. 11, pp. 1358-1365, 2003.
27. W. M. Foster, D. M. Walters, M. Longphre, K. Macri, and L. M. Miller, "Methodology for the measurement of mucociliary function in the mouse by scintigraphy," Journal of Applied Physiology, vol. 90, no. 3, pp. 1111-1117, 2001.
28. V. de Vooght, J. A. J. Vanoirbeek, S. Haenen, E. Verbeken, B. Nemery, and P. H. M. Hoet, "Oropharyngeal aspiration: an alternative route for challenging in a mouse model of chemical-induced asthma," Toxicology, vol. 259, no. 1-2, pp. 84-89, 2009.
29. D. M. Walters and S. R. Kleeberger, "Mouse models of bleomycin-induced pulmonary fibrosis," in Current Protocols in Pharmacology, chapter 5:unit 5.46, 2008.
30. C. Egger, C. Cannet, C. Gérard et al., "Administration of bleomycin via the oropharyngeal aspiration route leads to sustained lung fibrosis in mice and rats as quantified by UTE-MRI and histology," PLoS ONE, vol. 8, no. 5, Article ID e63432, 2013.
31. R. Lizio, A. Westhof, C.-M. Lehr, and T. Klenner, "Oral endotracheal intubation of rats for intratracheal instillation and aerosol drug delivery," Laboratory Animals, vol. 35, no. 3, pp. 257-260, 2001.
32. R. Lizio, D. Marx, T. Nolte et al., "Development of a new aerosol delivery system for systemic pulmonary delivery in anaesthetized and orotracheal intubated rats," Laboratory Animals, vol. 35, no. 3, pp. 261-270, 2001.
33. M. Bivas-Benita, R. Zwier, H. E. Junginger, and G. Borchard, "Non-invasive pulmonary aerosol delivery in mice by the endotracheal route," European Journal of Pharmaceutics and Biopharmaceutics, vol. 61, no. 3, pp. 214-218, 2005.
34. J. E. Phillips, R. Peng, L. Burns et al., "Bleomycin induced lung fibrosis increases work of breathing in the mouse," Pulmonary Pharmacology and Therapeutics, vol. 25, no. 4, pp. 281-285, 2012.
35. A. G. Rosas-Taraco, D. M. Higgins, J. Sánchez-Campillo, E. J. Lee, I. M. Orme, and M. González-Juarrero, "Intrapulmonary delivery of XCL1-targeting small interfering RNA in mice chronically infected with Mycobacterium tuberculosis," The American Journal of Respiratory Cell and Molecular Biology, vol. 41, no. 2, pp. 136-145, 2009.
36. A. G. Rosas-Taraco, D. M. Higgins, J. Sánchez-Campillo, E. J. Lee, I. M. Orme, and M. González-Juarrero, "Local pulmonary immunotherapy with siRNA targeting TGFβ1 enhances antimicrobial capacity in Mycobacterium tuberculosis infected mice," Tuberculosis, vol. 91, no. 1, pp. 98-106, 2011.
37. A. Gazdhar, I. Grad, L. Tamò, M. Gugger, A. Feki, and T. Geiser, "The secretome of induced pluripotent stem cells reduces lung fibrosis in part by hepatocyte growth factor," Stem Cell Research &Therapy, vol. 5, article 123, 2014.
38. Q. Ye, Y. Li, H. Jiang et al., "Prevention of pulmonary fibrosis viatrichostatin A (TSA) in bleomycin induced rats," Sarcoidosis, Vasculitis and Diffuse Lung Diseases, vol. 31, pp. 219-226, 2014.
39. Z. I. Cleveland, R. S. Virgincar, Y. Qi, S. H. Robertson, S. Degan, and B. Driehuys, "3D MRI of impaired hyperpolarized 129Xe uptake in a rat model of pulmonary fibrosis," NMR in Biomedicine, vol. 27, no. 12, pp. 1502-1514, 2014.